Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
70
EBS Quote, Financials, Valuation and Earnings
Last price:
$12.06
Seasonality move
:
3.87%
Day range:
$11.52 - $12.28
52-week range:
$4.02 - $13.41
Dividend yield:
0%
P/E ratio:
9.31x
P/S ratio:
0.85x
P/B ratio:
1.09x
Volume:
1.1M
Avg. volume:
1.3M
1-year change:
27.78%
Market cap:
$632.9M
Revenue:
$1B
EPS (TTM):
$1.29
Analysts' Opinion
-
Consensus RatingEmergent BioSolutions, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $13.50, Emergent BioSolutions, Inc. has an estimated upside of 12.03% from its current price of $12.05.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.00 representing 100% downside risk from its current price of $12.05.
Fair Value
-
According to the consensus of 2 analysts, Emergent BioSolutions, Inc. has 12.03% upside to fair value with a price target of $13.50 per share.
EBS vs. S&P 500
-
Over the past 5 trading days, Emergent BioSolutions, Inc. has overperformed the S&P 500 by 8.92% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Emergent BioSolutions, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Emergent BioSolutions, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Emergent BioSolutions, Inc. reported revenues of $231.1M.
Earnings Growth
-
Emergent BioSolutions, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Emergent BioSolutions, Inc. reported earnings per share of $0.91.
Enterprise value:
1.1B
EV / Invested capital:
0.84x
Price / LTM sales:
0.85x
EV / EBIT:
9.09x
EV / Revenue:
1.34x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
753.33x
Price / Operating cash flow:
478.13x
Enterprise value / EBITDA:
4.89x
Gross Profit (TTM):
$363.1M
Return On Assets:
5.29%
Net Income Margin (TTM):
9.62%
Return On Equity:
14.25%
Return On Invested Capital:
6.29%
Operating Margin:
33.23%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $1.1B | $1.1B | $788.9M | $293.8M | $231.1M | |
| Gross Profit | $306.3M | $319.6M | $363.1M | $159.9M | $129.1M | |
| Operating Income | -$205.6M | -$90.4M | $116M | $70.8M | $76.8M | |
| EBITDA | -$66.7M | $25.4M | $215.8M | $97.9M | $100.6M | |
| Diluted EPS | -$15.71 | -$4.10 | $1.29 | $2.06 | $0.91 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.1B | $1.1B | $711.4M | $661.4M | $786.9M | |
| Total Assets | $2.9B | $2.9B | $1.9B | $1.5B | $1.5B | |
| Current Liabilities | $365.4M | $268.4M | $664M | $229.9M | $136.5M | |
| Total Liabilities | $1.3B | $1.5B | $1.2B | $969.4M | $878.5M | |
| Total Equity | $1.5B | $1.4B | $697.2M | $508.4M | $582.5M | |
| Total Debt | $879.1M | $1.1B | $876.4M | $673.3M | $669.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$145.6M | $170.7M | $13M | $153.7M | -$2.3M | |
| Cash From Investing | $178.3M | $85.2M | $101.9M | $112M | -$3.4M | |
| Cash From Financing | -$187.3M | -$185.8M | -$22.2M | -$180.3M | -$15.9M | |
| Free Cash Flow | -$209.4M | $138.1M | $1.4M | $147.9M | -$5.7M | |
EBS
Sector
Market Cap
$632.9M
$28.4M
Price % of 52-Week High
89.86%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
11.87%
-1.32%
1-Year Price Total Return
27.78%
-22.19%
Beta (5-Year)
2.318
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$11.16
200-day SMA
Buy
Level
$7.45
Bollinger Bands (100)
Buy
Level
7.48 - 10.4
Chaikin Money Flow
Sell
Level
-103.2M
20-day SMA
Buy
Level
$10.60
Relative Strength Index (RSI14)
Buy
Level
64.56
ADX Line
Buy
Level
14.37
Williams %R
Sell
Level
-7.0552
50-day SMA
Buy
Level
$10.05
MACD (12, 26)
Buy
Level
0.39
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Neutral
Level
264.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.112)
Sell
CA Score
(Annual)
Level (-1.062)
Buy
Beneish M-Score
(Annual)
Level (-3.5433)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (2.937)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.
Stock Forecast FAQ
In the current month, EBS has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The EBS average analyst price target in the past 3 months is $13.50.
-
Where Will Emergent BioSolutions, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Emergent BioSolutions, Inc. share price will rise to $13.50 per share over the next 12 months.
-
What Do Analysts Say About Emergent BioSolutions, Inc.?
Analysts are divided on their view about Emergent BioSolutions, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Emergent BioSolutions, Inc. is a Sell and believe this share price will drop from its current level to $12.00.
-
What Is Emergent BioSolutions, Inc.'s Price Target?
The price target for Emergent BioSolutions, Inc. over the next 1-year time period is forecast to be $13.50 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is EBS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Emergent BioSolutions, Inc. is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of EBS?
You can purchase shares of Emergent BioSolutions, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Emergent BioSolutions, Inc. shares.
-
What Is The Emergent BioSolutions, Inc. Share Price Today?
Emergent BioSolutions, Inc. was last trading at $12.06 per share. This represents the most recent stock quote for Emergent BioSolutions, Inc.. Yesterday, Emergent BioSolutions, Inc. closed at $12.05 per share.
-
How To Buy Emergent BioSolutions, Inc. Stock Online?
In order to purchase Emergent BioSolutions, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get EBS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
EBS
Sector
P/E ratio
9.31x
23.66x
PEG ratio
-0.01x
-0.01x
P/B ratio
1.09x
1.84x
Price / LTM sales
0.85x
1.60x
Growth Metrics
EBS
Sector
Revenue growth
-21.34%
4.85%
Earnings growth
-56.11%
11.15%
Revenue (5-year growth)
-1.16%
6.45%
Earnings forecast
-$0.12
-$0.20
Profitability
EBS
Sector
Profitability FY 2024
$305.2M
$3.6M
Return on invested capital
6.29%
-30.98%
Return on assets
5.29%
-27.62%
Return on equity
14.25%
-36.69%
Earnings Date
Last Earnings Date
Oct
29
Next Earnings Date
Mar
4
Estimated Next Earnings Date
Jan
28
Balance Sheet
EBS
Sector
Total cash
$249.2M
$27.2M
Short term investments
--
$25.7M
Total assets
$1.4B
$79.9M
Long term debt
$669.2M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
44
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
